RT Journal Article
SR Electronic
T1 Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.06.21261721
DO 10.1101/2021.08.06.21261721
A1 Abe, Kento T.
A1 Hu, Queenie
A1 Mozafarihashjin, Mohammad
A1 Samson, Reuben
A1 Manguiat, Kathy
A1 Robinson, Alyssia
A1 Rathod, Bhavisha
A1 Wang, Jenny H.
A1 Iskilova, Mariam
A1 Pasculescu, Adrian
A1 Fazel-Zarandi, Mahya
A1 Li, Angel
A1 Paterson, Aimee
A1 Chao, Gary
A1 Green, Karen
A1 Gilbert, Lois
A1 Barati, Shiva
A1 Haq, Nazrana
A1 Takaoka, Alyson
A1 Takaoka, Julia Garnham
A1 De Launay, Keelia Quinn
A1 Fahim, Christine
A1 Sheikh-Mohamed, Salma
A1 Arita, Yuko
A1 Durocher, Yves
A1 Marcusson, Eric G.
A1 Gommerman, Jennifer L.
A1 Ostrowski, Mario
A1 Colwill, Karen
A1 Straus, Sharon E.
A1 Wood, Heidi
A1 McGeer, Allison J.
A1 Gingras, Anne-Claude
YR 2021
UL http://medrxiv.org/content/early/2021/08/08/2021.08.06.21261721.abstract
AB Prioritizing Ontario’s long-term care home (LTCH) residents for vaccination against severe acute respiratory syndrome coronavirus 2 has drastically reduced their disease burden; however, recent LTCH outbreaks of variants of concern (VOCs) have raised questions regarding their immune responses. In 198 residents, mRNA vaccine dose 1 elicited partial spike and receptor binding domain antibody responses, while the second elicited a response at least equivalent to convalescent individuals in most residents. Residents administered mRNA-1273 (Moderna) mounted stronger total and neutralizing antibody responses than those administered BNT162b2 (Pfizer-BioNTech). Two to four weeks after dose 2, residents (n = 119, median age 88) produced 4.8–6.3-fold fewer neutralizing antibodies than staff (n = 78; median age 47) against wild-type (with D614G) pseudotyped lentivirus, and residents administered BNT162b2 produced 3.89-fold fewer neutralizing antibodies than those who received mRNA-1273. These effects were exacerbated upon serum challenge with pseudotyped VOC spike, with up to 7.94-fold reductions in B.1.351 (Beta) neutralization. Cumulatively, weaker vaccine stimulation, age/comorbidities, and the VOC produced an ∼130-fold reduction in apparent neutralization titers in LTCH residents and 37.9% of BNT162b2-vaccinated residents had undetectable neutralizing antibodies to B.1.351. Continued immune response surveillance and additional vaccine doses may be required in this population with known vulnerabilities.Competing Interest StatementMAO and ACG receive funds from a research contract with Providence Therapeutics Holdings, Inc. for other projects. EGM is a co-founder of Providence Therapeutics Holdings, Inc., and YA is an employee there. Both are listed as inventors on patents and patent applications on SARS-CoV-2 mRNA vaccines. AJM has received funds for investigator-initiated research grants from Pfizer, Inc, and funds for participation in advisory boards from Pfizer and Moderna. All other authors have declared that no conflict of interest exists.Funding StatementThis work was supported by a COVID-19 Immunity Task Force (CITF) award to Sharon E. Straus, Allison J. McGeer, Jennifer L. Gommerman, Mario Ostrowski and Anne-Claude Gingras (Wellness Hub). This work was also supported by funding from the Canadian Institutes of Health Research and Public Health Agency of Canada (through the CITF) to Anne-Claude Gingras, Allison J. McGeer and Mario Ostrowski (VOC neutralization in LTC settings). We also acknowledge support from Ontario Together and funding from the Canadian Institutes of Health Research (#VR1-172711 and #439999). Funding for initial assay development in the Gingras lab was provided through generous donations from the Royal Bank of Canada and the Krembil Foundation (via the Sinai Health Foundation). The robotics equipment used is housed in the Network Biology Collaborative Centre at the Lunenfeld-Tanenbaum Research Institute, a facility supported by the Canada Foundation for Innovation, the Ontario Government, and Genome Canada and Ontario Genomics (OGI-139). The Pandemic Response Challenge Program of the NRC supported the design, production, purification and analysis of the antigens and antibodies used in the automated ELISA assays. Anne-Claude Gingras, Sharon Straus and Jennifer L. Gommerman are Canada Research Chairs (Tier 1) in Functional Proteomics; Knowledge Translation and Quality of Care; and Tissue Specific Immunity, respectively. Anne-Claude Gingras and Jennifer L. Gommerman are pillar leads for the Coronavirus Variants Rapid Response Network (CoVaRR-Net).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:REB approval was received from the Sinai Health System (20-0339-E). Informed consent was obtained from LTHC staff, essential caregivers and residents or their substitute decision-makers.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAdditional data is available from the authors